Health
Avacta and Daewoong Pharmaceutical expand partnership to include COVID-19 neutralising Affimer therapy – News-Medical.net
Avacta Group plc, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co.Ltd and AffyXell Therapeutics.
Avacta Group plc, the developer of Affimer® biotherapeutics and reagents, is pleased to announce an expansion of its collaboration and license agreement with Daewoong Pharmaceutical Co. Ltd. and AffyXell Therapeutics, the joint venture established in South Korea by the two companies, to develop stem cell treatments incorporating Avacta’s neutralising Affimer therapy for the treatment of seriously ill patients with COVID-19 and to also prepare to rapidly develop similar therapies for future globa…
-
General19 hours agoByford rail extension opening marks final stage of Perth Metronet
-
General21 hours agoMango the muster cat draws attention to western Queensland’s ongoing recovery
-
Business23 hours agoWhat $10,000 invested in the iShares S&P 500 IVV ETF could be in 10 years
-
General12 hours agoAustralia’s Diamonds defeat South Africa’s Proteas 65-42 in third netball Test